Top

Published in:

Open Access 01-12-2017 | Research article

Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding

Authors: Edita Baltruskeviciene, Diana Schveigert, Vaidotas Stankevicius, Ugnius Mickys, Tadas Zvirblis, Jaroslav Bublevic, Kestutis Suziedelis, Eduardas Aleknavicius

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

MiRNAs are often deregulated in colorectal cancer and might function as tumor suppressors or as oncogenes. They participate in controlling key signaling pathways involved in proliferation, invasion and apoptosis and may serve as prognostic and predictive markers. In this study we aimed to evaluate the role of miRNA-148a and miRNA-625-3p in metastatic colorectal cancer.

Methods

Fifty-four patients with a first-time diagnosed CRC receiving FOLFOX ± Bevacizumab were involved in the study. Tumor samples underwent routine pathology examination including evaluation for tumor budding and KRAS. MiRNA-148a and miRNA-625-3p expression analysis was done by RT-PCR. Associations between expression of both miRNAs and clinico-pathological factors, treatment outcomes and survival were analyzed.

Results

Both miRNA-148a and miRNA-625-3p were down-regulated in the tumors compared to normal colonic mucosa. Significantly lower expression of both miRNAs was noticed in tumors with budding phenomenon compared to tumors without it (median values of miRNA-148a were 0.314 and 0.753 respectively, p = 0.011, and 0.404 and 0.620 respectively for miRNA-625-3p, p = 0.036). Significantly lower expression of miRNA-625-3p was detected in rectal tumors, compared to tumors in the colon (median 0.390 and 0.665 respectively, p = 0.037). Progression free survival was significantly lower in patients with high miRNA-148a expression (6 and 9 months respectively, p = 0.033), but there were no significant differences in PFS for miRNA-625-3p and in overall survival for both miRNAs.

Conclusions

There was a significant relationship between low miRNA-148a and miRNA-625-3p expression and tumor budding, which is thought to represent epithelial-mesenchymal transition. Both studied miRNAs may be associated with a more aggressive phenotype and could be the potential prognostic and predictive biomarkers in CRC. Further investigation is needed to confirm miRNAs involvement in EMT, and their prognostic and predictive value.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine. 2009;360(14):1408–17. doi:10.1056/Nejmoa0805019.CrossRefPubMed

Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:64–72. doi:10.1093/annonc/mdt354.CrossRef

Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, et al. Tumor budding in colorectal carcinoma confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol. 2015;39(10):1340–6. doi:10.1097/PAS.0000000000000504.CrossRefPubMedPubMedCentral

Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer-ready for diagnostic practice? Hum Pathol. 2016;47(1):4–19. doi:10.1016/j.humpath.2015.08.007.CrossRefPubMed

Dawson H, Lugli A. Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne). 2015;2:11. doi:10.3389/fmed.2015.00011.

Grigore AD, Jolly MK, Jia DY, Farach-Carson MC, Levine H. Tumor Budding: The Name is EMT. Partial EMT. Journal of Clinical Medicine. 2016;5(5):51. doi:10.3390/jcm5050051.CrossRef

Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. doi:10.1016/S0092-8674(04)00045-5.CrossRefPubMed

Okugawa Y, Toiyama Y, Goel A. An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn. 2014;14(8):999–1021. doi:10.1586/14737159.2014.946907.CrossRefPubMedPubMedCentral

10.

Hong L, Han Y, Yang JJ, Zhang HW, Zhao QC, Wu KC, et al. MicroRNAs in gastrointestinal cancer: prognostic significance and potential role in chemoresistance. Expert Opin Biol Ther. 2014;14(8):1103–11. doi:10.1517/14712598.2014.907787.CrossRefPubMed

11.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299(4):425–36. doi:10.1001/Jama.299.4.425.CrossRefPubMedPubMedCentral

12.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–61. doi:10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral

13.

Luo XY, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomark Prev. 2011;20(7):1272–86. doi:10.1158/1055-9965.EPI-11-0035.CrossRef

14.

Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Molecular Cancer. 2006;5:29. doi:10.1186/1476–4598–5-29.CrossRefPubMedPubMedCentral

15.

Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol. 2014;20(33):11727–35. doi:10.3748/wjg.v20.i33.11727.CrossRefPubMedPubMedCentral

16.

Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, et al. Identification of a Metastasis-Specific MicroRNA Signature in Human Colorectal Cancer. J Natl Cancer Inst. 2015;107(3) doi:10.1093/jnci/dju492.

17.

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014;8(1):59–67. doi:10.1016/j.molonc.2013.09.001.CrossRefPubMed

18.

Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A et al. The Clinical Significance of MiR-148a as a Predictive Biomarker in Patients with Advanced Colorectal Cancer. Plos One. 2012;7(10). doi:ARTN e46684. doi:10.1371/journal.pone.0046684.

19.

Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Romer MU, Stenvang J, et al. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7(3):637–46. doi:10.1016/j.molonc.2013.02.016.CrossRefPubMedPubMedCentral

20.

Xue J, Chen Z, Gu X, Zhang Y, Zhang W. MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. Tumour Biol. 2016;37(2):1581–90. doi:10.1007/s13277-015-3926-9.CrossRefPubMed

21.

Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting met/Snail signaling. Oncogene. 2014;33(31):4069–76. doi:10.1038/onc.2013.369.CrossRefPubMed

22.

Qin Z, He W, Tang J, Ye Q, Dang W, Lu Y, et al. MicroRNAs provide feedback regulation of epithelial-Mesenchymal transition induced by growth factors. J Cell Physiol. 2016;231(1):120–9. doi:10.1002/jcp.25060.CrossRefPubMed

23.

Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705. doi:10.1016/j.humpath.2012.07.026.CrossRefPubMed

24.

Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Research. 2013;41(Web Server issue):W169-WW73. doi:10.1093/nar/gkt393.

25.

Chou C-H, Chang N-W, Shrestha S, Hsu S-D, Lin Y-L, Lee W-H, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 2016;44(Database issue):D239–D47. doi:10.1093/nar/gkv1258.CrossRefPubMed

26.

Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(W1):W77–83. doi:10.1093/nar/gkt439.CrossRefPubMedPubMedCentral

27.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

28.

Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions-beyond repression of gene expression. Nature Reviews Genetics. 2014;vol 15:pg 599. 2014;15(10):702.

29.

Sakamoto N, Naito Y, Oue N, Sentani K, Uraoka N, Oo HZ, et al. MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis. Cancer Sci. 2014;105(2):236–43. doi:10.1111/cas.12330.CrossRefPubMedPubMedCentral

30.

Joshi P, Jeon YJ, Lagana A, Middleton J, Secchiero P, Garofalo M, et al. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci U S A. 2015;112(28):8650–5. doi:10.1073/pnas.1500886112.CrossRefPubMedPubMedCentral

31.

Hibino Y, Sakamoto N, Naito Y, Goto K, Oo HZ, Sentani K, et al. Significance of miR-148a in colorectal Neoplasia: Downregulation of miR-148a contributes to the carcinogenesis and cell invasion of colorectal cancer. Pathobiology. 2015;82(5):233–41. doi:10.1159/000438826.CrossRefPubMed

32.

Tsai HL, Yang IP, Huang CW, Ma CJ, Kuo CH, Lu CY, et al. Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection. Transl Res. 2013;162(4):258–68. doi:10.1016/j.trsl.2013.07.009.CrossRefPubMed

33.

Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14(7):1170–9. doi:10.1007/s11605-010-1202-2.CrossRefPubMed

34.

Huang Y, Yu HJ, Lei H, Xie CH, Zhong YH. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients. Medical Oncology. 2014;31(3) doi:10.1007/S12032-013-0824-0.

35.

Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011;18(11):1702–10. doi:10.1038/cdd.2011.28.CrossRefPubMedPubMedCentral

36.

Zhan Q, Fang Y, Deng XX, Chen H, Jin JB, Lu XX, et al. The interplay between miR-148a and DNMT1 might be exploited for pancreatic cancer therapy. Cancer Investig. 2015;33(7):267–75. doi:10.3109/07357907.2015.1025794.CrossRef

37.

Yu J, Li Q, Xu Q, Liu L, Jiang B. MiR-148a inhibits angiogenesis by targeting ERBB3. J Biomed Res. 2011;25(3):170–7. doi:10.1016/S1674-8301(11)60022-5.CrossRefPubMedPubMedCentral

38.

Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Investig. 2011;91(10):1472–9. doi:10.1038/labinvest.2011.99.CrossRefPubMed

39.

Chen Y, Song YX, Wang ZN. The MicroRNA-148/152 Family: Multi-faceted Players. Molecular Cancer. 2013;12 doi:10.1186/1476–4598–12-43.

40.

De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Arch. 2016;468(4):397–408. doi:10.1007/s00428-015-1886-5.CrossRefPubMed

41.

Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, et al. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J Pathol. 2014;234(3):410–22. doi:10.1002/path.4416.CrossRefPubMed

42.

Masugi Y, Yamazaki K, Hibi T, Aiura K, Kitagawa Y, Sakamoto M. Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer. Hum Pathol. 2010;41(8):1061–8. doi:10.1016/j.humpath.2010.01.016.CrossRefPubMed

43.

Jensen DH, Dabelsteen E, Specht L, Fiehn AMK, Therkildsen MH, Jonson L, et al. Molecular profiling of tumour budding implicates TGF-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma. J Pathol. 2015;236(4):505–16. doi:10.1002/path.4550.CrossRefPubMed

44.

Wang M, Li CL, Nie H, Lv X, Qu Y, Yu BQ, et al. Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett. 2012;586(16):2382–8. doi:10.1016/j.febslet.2012.05.050.CrossRefPubMed

45.

Wang ZQ, Qiao Q, Chen M, Li XH, Wang ZJ, Liu CX, et al. miR-625 down-regulation promotes proliferation and invasion in esophageal cancer by targeting Sox2. FEBS Lett. 2014;588(6):915–21. doi:10.1016/j.febslet.2014.01.035.CrossRefPubMed

46.

Lou XL, Qi XL, Zhang Y, Long HD, Yang JJ. Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer. J Surg Oncol. 2013;108(4):230–5. doi:10.1002/jso.23380.CrossRefPubMed

47.

Li C, Li DC, Che SS, Ma K, Wang YJ, Xia LH, et al. The decreased expression of miR-625 predicts poor prognosis of esophageal squamous cell carcinoma. Int J Clin Exp Med. 2015;8(6):9560–4.PubMedPubMedCentral

48.

Zheng HL, Ma RQ, Wang QZ, Zhang P, Li DP, Wang QW, et al. MiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells. Oncotarget. 2015;6(29):27805–15. 10.18632/oncotarget.4738.CrossRefPubMedPubMedCentral

49.

Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol. 2000;18(23):3936–45.CrossRefPubMed

Title: Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding
Authors: Edita Baltruskeviciene
Diana Schveigert
Vaidotas Stankevicius
Ugnius Mickys
Tadas Zvirblis
Jaroslav Bublevic
Kestutis Suziedelis
Eduardas Aleknavicius
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3575-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-based multicentre randomized controlled trial

Galectin 3 expression in primary oral squamous cell carcinomas

Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5

Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer